Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
54 enrolled 18 charts
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Phase 1/2 Completed
63 enrolled 16 charts
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
Phase 1/2 Completed
22 enrolled 14 charts
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase 1/2 Completed
38 enrolled 12 charts
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase 1/2 Completed
70 enrolled 26 charts
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Phase 1/2 Completed
4 enrolled
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Phase 1/2 Completed
35 enrolled 13 charts
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
Phase 1/2 Completed
24 enrolled
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Phase 1/2 Completed
148 enrolled
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Phase 1/2 Completed
40 enrolled 12 charts
LCCC0510
Phase 1/2 Completed
54 enrolled 17 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Phase 1/2 Completed
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
Phase 1/2 Completed
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Phase 1/2 Completed
47 enrolled
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Completed
46 enrolled
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
14 enrolled
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Completed
33 enrolled
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
Phase 1/2 Completed
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Phase 1/2 Completed
9 enrolled
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
Phase 1/2 Completed
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase 1/2 Completed
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase 1/2 Completed
20 enrolled
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Phase 1/2 Completed